Table 2.
Comparison of mean dose and biologically effective dose (using either α/β = 10 Gy (BED10) or 3 Gy (BED3) for tumor volumes and α/β = 3 Gy for all OARs) between sequential boost (SEQ) and the simultaneous integrated boost (SIB) schemes for all structures of the ten studied patients (mean ± SD)
| SEQ | SIB10 | SIB3 | |||||
|---|---|---|---|---|---|---|---|
| Dose (Gy) | BED10 (Gy10) | BED3 (Gy3) | Dose (Gy) | BED10 (Gy10) | Dose | BED3 (Gy3) | |
| PTVboost Prescription | 66.0 | 79.2 | 110.0 | 64.4 | 79.2 | 62.9 | 110.0 |
| PTVbreast Prescription | 50.0 | 60.0 | 83.3 | 50.4 | 60.0 | 51.5 | 83.3 |
| PTVboost | 65.7 ± 0.7 | 78.7 ± 1.0 | 109.2 ± 1.7 | 64.2 ± 0.1 | 78.9 ± 0.1 | 62.6 ± 0.1 | 109.4 ± 0.3 |
| PTVbreast | 53.4 ± 0.7 | 63.8 ± 0.8 | 88.0 ± 1.0 | 52.2 ± 0.4 | 61.9 ± 0.6 | 52.8 ± 0.5 | 86.2 ± 1.0 |
| ILung | 9.0 ± 1.8 | 12.2 ± 2.7 | 8.2 ± 1.7 | 11.0 ± 2.5 | 8.2 ± 1.6 | 10.9 ± 2.4 | |
| CBreast | 1.2 ± 0.4 | 1.3 ± 0.4 | 1.1 ± 0.3 | 1.2 ± 0.3 | 1.1 ± 0.2 | 1.2 ± 0.3 | |
| CLung | 1.0 ± 0.3 | 1.0 ± 0.4 | 0.9 ± 0.2 | 0.9 ± 0.3 | 0.9 ± 0.2 | 0.9 ± 0.2 | |
| Heart (Lt.) | 3.4 ± 0.7 | 3.9 ± 1.1 | 3.0 ± 0.9 | 3.5 ± 1.2 | 3.2 ± 0.7 | 3.6 ± 1.0 | |
| Heart (Rt.) | 2.3 ± 0.5 | 2.4 ± 0.6 | 1.9 ± 0.2 | 2.0 ± 0.2 | 2.0 ± 0.6 | 2.1 ± 0.6 | |